![](/documents/2560328/2560686/hero-interior_Mobile.png/2da2806f-c12f-4301-afda-4f71eb2d4920?t=1529058304354)
![](/documents/2560328/2560686/hero-interior_Desktop.png/0b48085a-e573-4f80-a5a0-26c271803751?t=1529059064885)
Search Results
Frequently asked questions about PROLASTIN-C LIQUID
What is PROLASTIN-C LIQUID?
What is the PROLASTIN DIRECT program?
The PROLASTIN DIRECT program is a comprehensive program that uses experts exclusively dedicated to alpha-1 to provide unmatched personalized support for patients receiving
Starting your PROLASTIN-C LIQUID therapy
You may have questions about starting a new therapy, but it is important to remember that you are not alone.
![PROLASTIN-C Liquid trusted by patients with alpha-1 and their doctors icon](/documents/2560328/2560662/prolastin-c-liquid-trusted-patients-alpha-1-doctors_Desktop.png/72e41559-5b2a-4e20-adb2-147802149b04?t=1715611982742)
PROLASTIN-C LIQUID: The trusted leader for more than 30 years
PROLASTIN-C LIQUID is the #1 prescribed augmentation therapy, trusted by patients with alpha-1 and their doctors for more than 30 years. More than 4 million PROLASTIN-C infusions have been performed around the world.1
IMPORTANT SAFETY INFORMATION
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.